Melbourne, Australia; 12 October 2021: Further to the previous announcement on 8 October 2021, Starpharma (ASX: SPL, OTCQX: SPHRY) has been asked to provide additional information in relation to the sales and distribution agreement signed for the VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy. The agreement is a rolling annual supply contract for sales and distribution which provides the terms on which ADMENTA can acquire products from Starpharma for the Italian market for sale in its pharmacies, online and for distribution.
Exclusivity of agreement Supply contract is exclusive for retail pharmacies in Italy. The contract is not exclusive for online sales, and does not cover B2B sales, in Italy.
Regulatory registration The product is registered and no further registrations are required prior to sale.
Revenue estimates ADMENTA is required to launch in a minimum number pharmacies (>100) in Italy. There are no minimum order obligations.
Starpharma is currently unable to estimate revenue from sales of VIRALEZE™ in Italy.
